The Impact of Cannabidiol (CBD) Health Claims at Point-of-Sale on Consumer Perceptions and Behavior

销售点大麻二酚 (CBD) 健康声明对消费者认知和行为的影响

• 批准号: 10620707
• 负责人: Kimberly G. Wagoner
• 金额: $ 56.33万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620707
• 关键词: Address; Adult; Advertising; Age; Agriculture; Alzheimer' s Disease; Authorization documentation; Behavior; Benefits and Risks; Beverages; Cannabidiol; Cannabis; Cannabis policy; Cannabis sativa plant; Categories; Chemicals; Classification; Confusion; Cosmetics; Coupled; Development; Discipline; Drug Interactions; Drug Prescriptions; Drug abuse; Ensure; Environment; Epidiolex; Epilepsy; Expectancy; Explosion; Food; Food Additives; Future; Health; Hemp; Hepatotoxicity; Imaging technology; Industry; Intoxication; Laws; Letters; Mainstreaming; Malignant Neoplasms; Marijuana; Marketing; Medical; Methods; Nutritional; Online Systems; Outcome; Participant; Perception; Pharmaceutical Preparations; Photography; Policies; Policy Research; Predisposition; Prevalence; Psychotropic Drugs; Public Health; Randomized, Controlled Trials; Regulation; Report (document); Reporting; Research; Research Personnel; Research Priority; Risk; Safety; Sales; Sampling; Schedule; Science; Structure; Supervision; Surveys; Syndrome; Testing; Tetrahydrocannabinol; Therapeutic; Tobacco; Uncertainty; United States Food and Drug Administration; arm; authority; chronic pain; chronic pain relief; consumer behavior; dietary supplements; health communication; high risk; improved; innovation; interest; marijuana use; medical specialties; prevent; tobacco regulatory science; vaping; willingness

Project Summary Cannabidiol (CBD) products have rapidly gained popularity, with more than 46 million US adults reporting use, primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits, be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been unlawfully advertised online to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer, preventing Alzheimer’s disease and providing chronic pain relief. This a public health concern as these claims may reduce perceptions of harm, increase perceived benefits and influence consumers to delay medical treatment. Coupled with lacking scientific evidence on CBD’s safety and efficacy and uncertainty about product quality, consumers are at risk for unintended consequences including liver toxicity and adverse drug interactions with existing medications if they are misled about CBD’s risks and benefits by illicit health claims. This project, focused on informing regulatory actions for CBD, aims to document the types of health claims being made by brick and mortar CBD retailers, evaluate consumer perceptions of them, and assess their impact on consumer purchase of CBD. First, we will document health claims displayed in a large sample of CBD retailers from three states with contrasting cannabis policies. Our team and experts in cannabis, public health regulation and health communication will content analyze the health claims to identify potential FDA-prohibited claims. Next, we will assess consumer perceptions of the real-world CBD health claims by conducting a web-based survey with a nationally representative sample of 3,000 adult CBD users and non-users. Participants will assess if the claims indicate a FDA-prohibited category, share their interpreted meaning of each claim, and interest in trying CBD. Finally, in Aim 3, we will examine the impact of CBD health claims on consumer purchase behavior using a simulated retail environment. We will conduct a two-arm (CBD claims, no claim control) randomized controlled trial (RCT) in a simulated CBD retailer with 400 adult CBD users and susceptible non-users to evaluate the impact of CBD health claims on the purchase of CBD products (primary), willingness to try, perceived benefits, product safety, and outcome expectancies. The proposed study, informed by multiple disciplines including tobacco regulatory science and food and nutritional claims, will be the first to document health claims made by CBD retailers, assess consumer perceptions of those claims, and test the impact of claims on consumer behavior in a real-world RCT. This study will directly inform regulatory actions, assisting FDA in determining which claims consumers interpret in ways prohibited by law and ensuring consumers are not misled about CBD.

项目摘要 大麻二酚（CBD）产品已迅速越来越受欢迎，有超过4600万的美国成年人报告使用， 首先治疗医疗疾病。不断增长的CBD市场跨越了美国食品的一系列产品 和药物管理（FDA）调节，包括药物，饮食补充剂，食品/饮料和化妆品。 CBD不能被销售为具有治疗益处，对消费者是错误的或误导的，或传达 产品获得FDA的批准或认可。此外，CBD不能以食物添加剂或 饮食补充剂是因为它是批准的药物Epidiolex中的活性成分。尽管如此，CBD产品 已在网上向消费者进行了非法宣传，包括未经证实的健康索赔 这可以促进益处，包括治愈癌症，防止阿尔茨海默氏病并提供慢性疼痛。 这是公共卫生问题，因为这些主张可能会减少对伤害的看法，增加感知的福利和 影响消费者推迟医疗。加上缺乏有关CBD安全和的科学证据 效率和产品质量的不确定性，消费者面临意想不到的后果的风险 肝毒性和与现有药物的不良药物相互作用是否误导了CBD的风险和 非法健康索赔的益处。该项目旨在告知CBD的监管行动，旨在 记录实体CBD零售商所提出的健康索赔类型，评估消费者 对它们的看法，并评估他们对消费者购买CBD的影响。首先，我们将记录健康 来自三个州的CBD零售商样本中显示了索赔，这些零售商具有对比鲜明的大麻政策。我们的 大麻，公共卫生法规和健康沟通的团队和专家将满足于分析 卫生要求确定潜在的FDA逮捕索赔。接下来，我们将评估消费者对 现实世界中CBD健康要求通过与全国代表性样本进行基于网络的调查 3,000名成人CBD用户和非用户。参与者将评估索赔是否表示FDA违反类别， 分享他们对每种主张的解释含义，并有兴趣尝试CBD。最后，在AIM 3中，我们将研究 使用模拟零售环境，CBD健康索赔对消费者购买行为的影响。我们将 在模拟的CBD中进行两臂（CBD索赔，无主张控制）随机对照试验（RCT） 有400名成人CBD用户和易感非用户的零售商评估CBD健康索赔的影响 购买CBD产品（主要），尝试，感知的福利，产品安全和结果的意愿 期待。拟议的研究，由多个学科所启示，包括烟草监管科学和 食品和营养索赔将是第一个记录CBD零售商的健康索赔的人，评估消费者 对这些主张的看法，并测试索赔对现实世界中消费者行为的影响。这 研究将直接告知监管行动，协助FDA确定哪些主张消费者解释 法律禁止的方式和确保消费者对CBD的误解。

项目成果

Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.

• DOI: 10.3389/fpubh.2022.893009
• 发表时间: 2022
• 期刊: FRONTIERS IN PUBLIC HEALTH
• 影响因子: 5.2
• 作者: Dobbins, MaryBeth;Rakkar, Mannat;Cunnane, Katharine;Pennypacker, Sarah D.;Wagoner, Kimberly G.;Reboussin, Beth A.;Romero-Sandoval, E. Alfonso
• 通讯作者: Romero-Sandoval, E. Alfonso